insights_auto
Why is DMYD-B up 2.19%?
Dive Deeperchevron_right
DMYD-B:STO
Diamyd Medical AB
SEKÂ 0.98
arrow_upward
+2.19%(+0.021) 1D
Oct 9, 5:29:56 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEKÂ 0.95
High
SEKÂ 0.99
Low
SEKÂ 0.92
Mkt. cap
148.45M
Avg. vol.
759.33K
Volume
894.92K
52-wk high
SEKÂ 17.88
52-wk low
SEKÂ 0.90
EPS
-SEKÂ 1.98
Shares outstanding
134.00M
No. of employees
44
Open
SEKÂ 0.95
High
SEKÂ 0.99
Low
SEKÂ 0.92
Mkt. cap
148.45M
Avg. vol.
759.33K
Volume
894.92K
52-wk high
SEKÂ 17.88
52-wk low
SEKÂ 0.90
EPS
-SEKÂ 1.98
Shares outstanding
134.00M
No. of employees
44
News stories
From web sources and news partners
ChartMill
·
1 day ago
Get insights into the top movers in the S&P500 index of Friday's pre-market session.
BigGo Finance
·
23 hours ago
Tech Rebound Lifts All Three Major Indexes; Dow Posts Weekly Gain of Over 400 Points
The Motley Fool
·
6 hours ago
Prediction: This Is What a $5,000 Investment in the Vanguard S&P 500 ETF (VOO) Will Be Worth by 2040
The Washington Post
·
18 hours ago
How major US stock indexes fared Friday 10/9/2026
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB